ArticleFrontiers in immunology2025
Investigating the role of tumor cell heterogeneity and angiogenesis genes in the prognosis of multiple myeloma.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Correlation analysis of serum CCL3, TRACP-5b, and sclerostin with the prognosis of multiple myeloma patients.Journal of medical biochemistry · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Multiple myeloma (MM) is a common hematologic malignancy characterized by high tumor cell heterogeneity, which significantly impacts the clinical prognosis of patients. Angiogenesis and the molecular features of tumor cells play a critical role in tumor progression and drug resistance. This study aims to explore the impact of tumor cell heterogeneity and angiogenesis-related genes on the prognosis of MM. Methods: We collected transcriptomic data and single-cell RNA sequencing data from MM patients through the Xena and GEO databases. The data were processed and analyzed using bioinformatics methods, including differential gene expression analysis, single-cell clustering, CNV analysis, transcription factor analysis, screening of angiogenesis-related genes, cell communication analysis, and immune infiltration analysis. Results: Through integrative analysis of transcriptomic data and single-cell RNA sequencing data, we identified significant genomic copy number variations in the tumor cells of MM patients. Additionally, different tumor subgroups exhibited differences in angiogenic activity, gene expression, and tumor progression. Notably, high expression of the transcription factor cAMP-responsive element-binding protein 3-like 2 (CREB3L2) in the C1 subgroup was associated with the inhibition of angiogenesis and tumor cell proliferation and migration. Furthermore, the prognostic model based on angiogenesis and transcription factors demonstrated high accuracy in predicting the prognosis of MM patients. Conclusion: This study highlights the critical roles of tumor cell heterogeneity and angiogenesis-related genes in MM. By constructing a prognostic model, it provides new theoretical insights for the precise diagnosis and personalized treatment of MM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.